Kamada (NASDAQ:KMDA) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Friday.
A number of other brokerages have also commented on KMDA. Zacks Investment Research raised Kamada from a “sell” rating to a “hold” rating in a report on Wednesday, October 25th. Jefferies Group reissued a “buy” rating and set a $7.00 price objective on shares of Kamada in a report on Thursday, October 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $8.50.
Shares of Kamada (NASDAQ KMDA) traded down $0.05 on Friday, reaching $5.20. The company’s stock had a trading volume of 21,986 shares, compared to its average volume of 24,201. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.71 and a quick ratio of 2.73. The company has a market cap of $211.73, a price-to-earnings ratio of -129.97 and a beta of 1.04. Kamada has a 1 year low of $3.75 and a 1 year high of $8.61.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.chaffeybreeze.com/2018/01/05/kamada-kmda-upgraded-at-valuengine.html.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.